IMBdx (XKRX:461030) Buildings And Improvements : ₩0 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is IMBdx Buildings And Improvements?

IMBdx Buildings And Improvements Historical Data

The historical data trend for IMBdx's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IMBdx Buildings And Improvements Chart

IMBdx Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Buildings And Improvements

IMBdx Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Buildings And Improvements	Get a 7-Day Free Trial					-	-	-	-	-

IMBdx Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

IMBdx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IMBdx Inc (XKRX:461030) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

131 Gasandigital 1-ro, 21st Floor BYC Highcity Building A, Geumcheon-gu, Seoul, KOR, 08506

Website

https://www.imbdx.com

IMBdx Inc detects and analyzes the genomic profile of tumor DNA with a single draw of blood. It provides personalized and optimized analysis information that can be utilized in therapy selection and monitoring. Its AlphaLiquid platform offers ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection (AlphaLiquid 100/HRR) to recurrence and minimal residual disease(MRD) monitoring (CancerDetect), and multi-cancer early detection (CancerFind). Its services are Clinical Service BioPharma, Research, and Healthcare Checkup.

IMBdx Headlines

No Headlines